Sie befinden sich hier: Start > Medizinische Leistun... > Tumorzentrum Basel > Mitarbeitende > Prof. Dr. med. Markus Zuber

Mitarbeitende

Prof. Dr. med. Markus Zuber

Leitung St. Clara Forschung AG

Portrait Prof. Dr. med. Markus Zuber

Seit 2023
Leitung St. ClaraForschung AG

2020 -
Koordinator klinischer Studien der Clarunis Netzwerk-Kliniken

Seit 2014
Experte Fachorgan IVHSM

2000 - 2019
Chefarzt, Klinik für Viszeral-, Gefäss- und Thoraxchirurgie Kantonsspital Olten

2019 - 2020
Chefarzt a.i., Klinik für Viszeral-, Gefäss- und Thoraxchirurgie Bürgerspital Solothurn

2015 - 2019  
Ärztlicher Direktor der Solothurner Spitäler AG 

2006
Titularprofessur für Chirurgie der Universität Basel

2000
Habilitation, venia docendi

1996 - 2000
Leitender Oberarzt, Viszeralchirurgische Abteilung, Allgemeinchirurgische Klinik, Departement Chirurgie, Universität Basel

1995 - 1996
Oberarzt, Departement Chirurgie, Universität Basel

1993 - 1994
Oberarzt, Chirurgische Klinik, Stadtspital Triemli Zürich

1993
Facharzt FMH Chirurgie

1992 - 2000
Klinischer Forschungsgruppenleiter, Departemente Chirurgie und Forschung (ZLF) der Universität Basel

1990 - 1993
Oberarzt, Departement Chirurgie, Universität Basel

1990
Assistenzarzt, Departement Chirurgie, Universität Basel

1990
Promotion Universität Basel

1989
Assistenzarzt, Research Fellowship, Division of Surgical Oncology
(T.J. Eberlein), Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachussetts, USA

1987 - 1988
Assistenzarzt, Departement Chirurgie, Universität Basel

1986
Assistenzarzt, Chirurgische Abteilung, Spital Wattwil (B-Jahr)

1984 - 1985
Assistenzarzt, Departement Chirurgie, Universität Basel

1983
Assistenzarzt, Chirurgische Klinik, Kantonsspital Chur

1982
Staatsexamen Universität Basel

  • International Society of Surgery / Société Internationale de Chirurgie
  • Alumni Association of the Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
  • FMH für Chirurgie
  • Schweizerisch Gesellschaft für Chirurgie
  • European Society of Surgical Oncology
  • Deutsche Gesellschaft für Chirurgie
  • Chirurgische Arbeitsgemeinschaft für Onkologie, Deutsche Gesellschaft für Chirurgie
  • Schweizerische Arbeitsgemeinschaft für klinische Krebsforschung (Sektion Chirurgie, Gastrointestinale Tumor-Projektgruppe, Mammakarzinom-Projektgruppe)
  • College of the European School of Oncology
  • Schweizerische Gesellschaft für Senologie (Vorstand)
  • Verein der Schweizerischen Chef- und Leitenden Ärzte
  • Schweizerische Arbeitsgemeinschaft für laparoskopische und thorakoskopische Chirurgie
  • Schweizerische Gesellschaft für Viszeralchirurgie
  • Schweizerische Gesellschaft für Allgemein- und Unfallchirurgie
  • International Sentinel Node Society
  • Fakultätsmitglied des zweijährlichen, englischsprachigen
    International Symposium on Cancer Metastasis and the
    Lymphovascular System: Basis for Rational Therapy
    2011 New York City, 2013 San Francisco
  • Association for Research in Surgery (Vorstand) der Schweizerischen Gesellschaft für Chirurgie
  • Rueff J, Weixler B, Viehl TC, Ochsner A, Warschkow R, Gueller U, Mingrone W, Zuber M. Improved qualitity of colon cancer surveillance after implementation of a personalized surveillance schedule. J Surg Oncol 2020: published ahead of print, doi: 10.1002/jso.25973
  • Marti WR, Curti G, Wehrli H, Grieder F, Graf M, Gloor M, Zuber M, Demartines N, Fasolini F, Lerf B, Kettelhack C, Andrieu C, Bigler M, Hayoz S, Ribi K, Hamel C; Swiss Group for Clinical Cancer Research (SAKK), Section Surgery. Clinical outcome after rectal replacement with side-to-end, colon-j-pouch, or straight colorectal anastomosis following total mesorectal excision: a Swiss prospective, randomized, multicenter trial (SAKK 40/04). Ann Surg. 2019 May; 269(5):827-835
  • Ribi K, Marti WR, Bernhard J, Grieder F, Graf M, Gloor B, Curti G, Zuber M, Demartines N, Andrieu C, Bigler M, Hayoz S, Wehrli H, Kettelhack C, Lerf B, Fasolini F, Hamel C; Swiss Group for Clinical Cancer Research (SAKK), Section Surgery. Quality of life after total mesorectal excision and rectal replacement: comparing side-to-end, colon-j-pouch, and straight colorectal reconstruction in a randomized, phase III trial (SAKK 40/04). Ann Surg Oncol. 2019 Oct; 26(11):3568-3576
  • Jakob MO, Guller U, Ochsner A, Oertli D, Zuber M, Viehl CT. Lymph node ratio is inferior to pN-stage in predicting outcome in colon cancer patients with high numbers of analyzed lymph nodes. BMC Surg. 2018 Oct 3; 18(1): 81(1-7)
  • Hayoz C, Hermann T, Raptis DA, Brönnimann A, Peterli R, Zuber M. Comparison of metabolic outcome in patients undergoing laparoscopic Roux-en-Y gastric bypass versus sleeve gastrectomy – a systematic review and meta-analysis of randomized controlled trials. Swiss Med Wkly. 2018 Jul 5; 148: doi 10.4414/smw.2018.14633
  • Weixler B, Viehl CT, Warschkow R, Guller U, Ramser M, Sauter G, Zuber M. Comparative analysis of tumor cell dissemination to the sentinel lymph nodes and to the bone marrow in patients with non-metastasized colon cancer. A prospective multicenter study. JAMA Surg. 2017 Oct 1;152(10):912-920
  • Viehl CT, Weixler B, Güller U, Dell-Kuster S, Rosenthal R, Ramser M, Banz V, Langer I, Terracciano L, Sauter G, Oertli D, Zuber M. Presence of bone marrow micrometastases in stage I-III colon cancer patients is associated with worse disease-free and overall survival. Cancer Med. 2017 May;6(5):918-927
  • Weixler B, Rickenbacher A, Raptis DA, Viehl CT, Guller U, Rueff J, Zettl A, Zuber M. Sentinel lymph node mapping with isosulfan blue or indocyanine green in colon cancer shows comparable results and identifies patients with decreased survival: A prospective comparative single-center trial. World J Surg. 2017 Sep;41(9):2378-2386
  • Haueter R, Schütz T, Raptis DA, Clavien PA, Zuber M. Meta-analysis of single port versus conventional laparoscopic cholecystectomy comparing body image and cosmesis. Br J Surg 2017; 104(9):1141-1159
  • Jeger V, Pop R, Forudastan F, Barras JP, Zuber M, Piso RJ. Is there a role for procalcitonin in diffenrentiating uncomplicated and complicated diverticulitis in order to reduce antibiotic therapy? A prospective diagnostic cohort study. Swiss Med Wkly 2017 Nov 29; 147: w14555. doi: 10.4414/smw.2017.14555
  • Weixler B, Warschkow R, Güller U, Zettl A, von Holzen U, Schmied BM, Zuber M. Isolated tumor cells in stage I & II colon cancer patients are associated with significantly worse disease-free and overall survival. BMC Cancer 2016; 16: 106-113
  • GlobalSurg Collaborative. Mortality of emergency abdominal surgery in high-, middle- and low-income countries. Br J Surg 2016; 103(8):971-988
  • Amicarella F, Muraro MG, Hirt C, Cremonesi E, Padovan E, Mele V, Governa V, Han J, Huber X, Droeser RA, Zuber M, Adamina M, Bolli M, Rosso R, Lugli A, Zlobec I, Terracciano L, Tornillo L, Zajac P, Eppenberger-Castori S, Trapani F, Oertli D, Iezzi G. Dual role of tumour-infiltrating T helper 17 cells in human colorectal cancer. Gut 2015; 66(4): 692-704
  • Weixler B, Warschkow R, Zettl A, Riehle HM, Guller U, Viehl CT, Zuber M. Intranodal mapping using carbon dye results in more accurate lymph node staging in colon cancer patients. World J Surg 2015; 39: 2583-2389
  • Croner RS, Geppert C-I, Bader FG, Nitsche U, Späth C, Rosenberg R, Zettl A, Matias-Guiu X, Tarragona J, Güller U, Stürzl M, Zuber M. Molecular staging of lymph node-negative colon carcinomas by One-Step Nucleic Acid Amplification (OSNA) results in an upstaging of a quarter of patients in a prospective, European, multicenter study. Br J Cancer 2014; 110: 2544-2550
  • Langer I, Guller U, Worni M, Berclaz G, Singer G, Schaer G, Fehr MK, Hess T, Viehl, CT, Bronz L, Schnarwyler B, Wight E, Infanger E, Burger D, Koechli OR, Zuber M for the Swiss Sentinel Lymph Node Study Group in Breast Cancer. Bone marrow micrometastases do not impact disease-free and obverall survival in early stage sentinel nymph node-negative breast cancer patients. Ann Surg Oncol 2014; 21: 401-407
  • Droeser RA, Dell-Kuster S, Kurmann A, Rosenthal R, Zuber M, Metzger J, Oertli D, Hamel CT, Frey DM. Long-term follow-up of a randomized controlled trial of Lichtenstein’s operation versus mesh plug repair for inguinal hernia. Ann Surg 2014: 259: 966-972
  • Larusson HJ, von Holzen U, Viehl CT, Rezaeian F, Riehle HM, Oertli D, Guller U, Zuber M. Blue dye injection does not induce dissemination of epithelial cells during SLN procedure in colon cancer patients. Int J Colorectal Dis 2014; 29: 689-692
  • Nebiker CA, Han J, Eppenberger-Castori S, Iezzi G, Hirt C, Amicarella F, Cremonesi E, Huber X, Padovan E, Angrisani B, Droeser RA, Rosso R, Bolli M, Oertli D, von Holzen U, Adamina M Muraro MG, Mengus C, Zajac P, Sconoccha G, Zuber M, Tornillo L, Terracciano L, Spagnoli GC. GM-CSF production by tumor cells is associated with improved survival in colorectal cancer. Clin Cancer Res 2014; 15: 3094-3106
  • Meiers P, Cil T, Guller U, Zuber M. Sentinel lymph node biopsy in early-stage breast cancer patients: improved survival through better staging? Langenbecks Arch Surg 2013; 398:687-690
  • Droeser RA, Hirt C, Eppenberger-Castori S, Zlobec I, Viehl CT, Frey DM, Nebiker CA, Rosso R, Zuber M, Amicarella F, Iezzi G, Sconocchia G, Heberer M, Lugli A, Tornillo L, Oertli D, Terracciano L, Spagnoli G. High myeloperoxidase positive cell infiltration in colorectal cancer is an independent favourable prognostic factor. PLoS One 2013. Epub adhead of print. DOI 10.1371/journal.pone.0064814. Print 2013
  • Viehl CT, Guller U, Langer I, Laffer U, Oertli D, Zuber M. Factors influencing the success of in vivo sentinel lymph node procedure in colon cancer patients: Swiss prospective, multicenter study sentinel lymph node procedure in colon cancer. World J Surg 2013; 37: 873-877
  • Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, Zlobec I, Eppenberger-Castori S, Tzankov A, Rosso R, Zuber M, Muraro MG, Amicarella F, Cremonesi E, Heberer M, Iezzi G, Lugli A, Terracciano L, Sconocchia G, Oertli D, Spagnoli GC, Tornillo L. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013; 49: 2233-2242
  • Wanebo HJ, LeGolvan M, Paty PB, Saha S, Zuber M, D’Angelica MI, Kemeny NE. Meeting the biological challenge of colorectal metastases. Clin Exp Metastasis 2012: 29: 821-839
  • Guller U, Zettl A, Langer I, Cabalzar-Wondberg D, Rezaeian F, Viehl CT, Demartines N, Zuber M. Molecular investigation of lymph nodes in colon cancer patients: a new road to better staging? Cancer 2012; 118: 6039-6045
  • Viehl CT, Guller U, Cecini R, Langer I, Ochsner A, Terracciano L, Riehle HM, Laffer U, Oertli D, Zuber M. Sentinel lymph node procedure leads to upstaging of patients with resectable colon cancer. Results of the Swiss prospective, multicenter study sentinel lymph node procedure in colon cancer. Ann Surg Oncol 2012; 19: 1959-1965
  • Strauss und Torney M, Rezaeian F, Loher S, Brosi P, Guller U, Terracciano L, Zuber M. Tissue banking in a regional hospital: a promising future concept? First report on fresh frozen tissue banking in a hospital without an integrated institute of pathology. World J Surg 2012; 36: 2300-2304
  • Von Holzen U, Gehrz A, Meier L, Zuber M. The AQC database represents a useful tool for quality control and scientific analysis of acute appendicitis. Swiss Med Wkly 2012; 142. doi: 10.4414/smw.2012.13617
  • Sonocchia G, Zlobec I, Lugli A, Calabrese D, Iezzi G, Karamitopoulou E, Patsouris ES, Peros G, Horcic M, Tornillo L, Zuber M, Droeser R, Muraro MG, Mengus C, Oertli D, Ferrone S, Terracciano L, Spagnoli G. Tumor infiltration by FcyRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. Int J Cancer 2011; 128: 2663 - 2672
  • Viehl CT, Langer I, Guller U, Zanetti-Dällenbach R, Moch H, Wight E, Oertli D, Zuber M.Prognostic impact and therapeutic implications of sentinel lymph node micro-metastases in early-stage breast cancer patients. J Surg Oncol 2011, 103: 531-533
  • Leong SPL, Zuber M, Ferris RL, Kitigawa Y, Cabanas, R, Levenback C, Faries M, Saha S. Impact of nodal status and tumor burden in sentinel lymph nodes on the clinical outcome of cancer patients. J Surg Oncol 2011; 103: 518-530
  • Viehl CT, Ochsner A, von Holzen U, Cecini R, Langer I, Guller U, Laffer U, Oertli D, Zuber M. Inadequate quality of surveillance after curative surgery for colon cancer. Ann Surg Oncol 2010; 17: 2663-2669
  • Langer I, Guller U, Viehl CT, Moch H, Wight E, Harder F, Oertli D, Zuber M. Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study. Ann Surg Oncol 2009; 16: 3366-3374
  • Langer I, Guller U, Hsu Schmitz SF, Ladewig A, Viehl CT, Moch H, Wight E, Harder F, Oertli D, Zuber M. Performing sentinel lymph node biopsy is associated with improved survival compared with level I & II axillary dissection in node negative breast cancer patients. Eur J Surg Oncol 2009; 35: 805-813
  • Langer I, Guller U, Berclaz G, Koechli OR, Moch H, Schaer G, Fehr M, Hess T, Oertli D, Bronz L, Schnarwyler B, Wight E, Uehlinger U, Infanger E, Burger D, Zuber M. Accuracy of frozen section of sentinel lymph nodes: a prospective analysis of 659 breast cancer patients of the Swiss multizenter study. Breast Cancer Res Treat 2009; 113: 129-136
  • Güller U, Kempski O, Zuber M. The bumpy path to successful academic surgery: a roadmap for the surgical resident. Eur Surg Res 2009; 43: 253-255
  • Rosenthal R, Viehl CT, Guller U, Weber WP, Adamina M, Spagnoli GC, Heberer M, Zuber M. Active specific immunotherapy phase III trials for malignant melanoma: systematic analysis and critical appraisal. J Am Coll Surg 2008; 207: 95-105
  • Adamina M, Weber WP, Rosenthal R, Schumacher R, Zajac P, Guller U, Frey DM, Oertli D, Zuber M, Heberer M, Spagnoli GC. Heterologous prime-boost immunotherapy of melanoma patients with influenza virosomes, and recombinant vaccinia virus encoding 5 melanoma epitopes and 3 co-stimularoy molecules. A multicenter phase I/II open labelled clinical trial. Surgery 2008; 29: 165-181
  • Lehmann K, Guller U, Bugnon S, Zuber M. Interdisciplinary tumour boards in Switzerland: quo vadis? Swiss Medical Weekly 2008; 138: 123-127
  • Laffer U, Metzger U, Aeberhard P, Lorenz M, Harder F, Maibach R, Zuber M, Herrmann R. Adjuvant perioperative portal vein or peripheral intravenous chemotherapiy for potentially curative colorectal cancer: long-term results of a randomized controlled trial. Int J Colorectal Dis 2008; 23: 1223-1241
  • Straumann A, Bussmann C, Zuber M, Vannini S, Simon HU, Schoepfer A. Eosinophilic esophagitis: analysis of food impactation and perforation in 251 adolescent and adult patients. Clin Gastroenteol Hepatol 2008; 6: 598-600
  • Zuber M, Viehl CT, Güller U, Langer I. Nachsorge-Empfehlungen für Patientinnen mit kurativ therapiertem, invasivem Mammakarzinom. Ther Umschau 2008; 65: 319-321
  • Langer I, Guller U, Berclaz G, Koechli OR, Schaer G, Fehr MK, Hess T, Oertli D, Bronz L, Schnarwyler B, Wight E, Uehlinger U, Infanger E, Burger D, Zuber M, for the Swiss Multicenter Study Group Sentinel Lymph Node in Breast Cancer. Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN & completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients Ann Surg 2007; 245: 452-461
  • Langer I, Guller U, Koechli OR, Berclaz G, Singer G, Schaer G, Fehr MK, Hess T, Oertli D, Bronz L, Schnrawyler B, Wight E, Uehlinger U, Infanger E, Burger D, Zuber M, for the Swiss Multicenter Sentinel Lymph Node Study Group in Breast Cancer. Association of the presence of bone marrow micrometastases with the sentinel lymph node status in 410 early stage breast cancer patients: Results of the Swiss multicenter study. Ann Surg Oncol 2007; 14: 1896-1903
  • Frey DM, Wildisen A, Hamel CT, Zuber M, Oertli D, Metzger J. Inguinal hernia repair: Lichtenstein versus mesh plug repair – a prospective randomized multicentre trial. Br J Surg 2007; 94: 63-4146. Viehl CT, Guller U, Hamel CT, Riehle HM, Plaass C, Marti WR, Oertli D, Zuber M. Carbon dye staining of sentinel lymph nodes facilitates microstaging of colon cancer patients. World J Surg 2006; 30: 453-456
  • Langer I, Marti WR, Guller U, Moch H, Harder F, Oertli D, Zuber M. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy. Ann Surg 2005; 241: 152-158
  • Köchli OR, Langer I, Berclaz G, Bischof T, Brun del Re R, Burkhard R, Delaloye JF, Diener PA, Haller U, Ries G, Schäfer P, Schär G, Steinert HC, von Orelli S, Zuber M. Sentinel-Lymphknotenbiopsie beim Mammakarzinom. Konsensusstatements der Schweizerischen Arbeitsgruppe Sentinel beim Mammakarzinom und der Arbeitsgemeinschaft der Gynäkologischen Onkologie (AGO). Schweiz Ärztezeitung 2005; 86: 48-56
  • Weber WP, Zanetti R, Langer I, Dellas S, Zuber M, Moch H, Remmel E, Oertli D, Wight E, Marti WR. Mammotome: Less invasive than ABBI with similar accuracy for early breast cancer detection. World J Surg 2005; 29: 495-499
  • Langer I, Kocher Th, Güller U, Torhorst J, Oertli D, Harder F, Zuber M. Long-term outcome of breast cancer patients after endoscopic axillary lymph nodes dissection: a prospective analysis of 52 patients. Breast Cancer Res Treat 2005; 90: 85-91
  • Al-Kuaya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M, Köchli OR, Zuber M, Dietrich H, Mross F, Wilber K, Simon R, Sauter G. Prognostic relevance of gene amplifications and coamplifictions in breast cancer. Cancer Res 2004; 64: 8534-8540
  • Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H, Maurer R, Metzger U, Von Castelberg B, Bart R, Stopatschinskaya S, Köchli OR, Haas P, Mross F, Zuber M, Dietrich H, Bischoff S, Mirlacher M, Sauter G, Gastl G. High Ep-CAM expression is associated with poor prognosis in node negative breast cancer. Breast Cancer Res Treat 2004; 86: 207-213
  • Viehl CT, Hamel CT, Marti WR, Güller U, Eisner L, Stammberger U, Terracciano L, Spichtin HP, Harder F, Zuber M. Identification of sentinel lymph nodes in colon cancer depends on the amount of dye injected relative to tumor size. World J Surg 2003; 27: 1285-1290
  • Güller U, Nitzsche E, Moch H, Zuber M. Is positron emission tomography an accurate non-invasive alternative to sentinel lymph node biopsy in breast cancer patients? J Natl Cancer Inst 2003; 95: 1040-1043
  • Zuber M, Oertli D, Marti WR, Kocher T, Wildisen A, Berclaz G, Köchli OR, Harder F für die Arbeitsgruppe FMH Guideline Mammakarzinom. FMH Guideline. Axillachirurgie beim Mammakarzinom. Schweiz Ärztezeitung 2003; 84: 1967-1973
  • Benz J, Berclaz G, Dupont Lampert V, Eicher E, Harder F, Köchli OR, Laffer UT, Poell JG, Trutmann M, Zuber M für die Arbeitsgruppe FMH Guideline Mammakarzinom, Chirurgische Therapie. FMH Guideline Tumorektomie oder Mastektomie? Wahl des Operationsverfahrens für Stadien T1-T3 NxM0 des Mammakarzinoms. Schweiz Ärztezeitung 2003; 84: 1956-1965
  • Van de Rijn M, Perrou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Kochli OR, Mross F, Dietrich H, Seitz R, Ross D, Botstein D, Brown P. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Path 2002; 161: 1991-1996
  • Güller U, Zajac P, Schnider A, Bösch B, Vorburger S, Zuber M, Spagnoli GC, Oertli D, Maurer R, Metzger U, Harder F, Heberer M, Marti WR. Disseminated single tumor cells as detected by real-time polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg 2002; 236: 768-776
  • Poremba C, Heine B, Diallo R, Heinecke A, Wai D, Schäfer KL, Braun Y, Schuck A, Lanvers C, Bankfalvi A, Kneif S, Torhorst J, Zuber M, Kochli OR, Mross F, Dietrich H, Sauter G, Stein H, Fogt F, Böcker W. Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J Path 2002; 198: 181-189
  • Güller U, Nitzsche EU, Schirp U, Viehl CT, Torhorst J, Moch H, Langer I, Marti WR, Oertli D, Harder F, Zuber M. Selektive axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2-deoxy-D-glucose: not yet. Breast Cancer Res Treat 2002; 71: 171-173
  • Güller U, Zuber M, Harder F. Zoekumvolvulus – ein diagnostisch häufig verpasstes Krankheitsbild. Ergebnisse einer retrospektiven Studie von 26 Patienten und Literaturübersicht. Swiss Surg 2001; 7: 158-164
  • Bittner C, Zuber M, Eisner L. Akute Ischämie der Hand bei einem Drogenabhängigen nach akzidenteller, intraarterieller Injektion. Swiss Surg 2002; 8: 281-284
  • Torhorst J, Bucher Ch, Kononen J, Haas Ph, Zuber M, Köchli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP, Sauter G. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Path 2001; 159: 2249-2256
  • Zuber M, Harder F. Mammakarzinom: Sentinel Lymph Node – Wächter intakter regionaler Lymphknoten. Praxis 2001; 90: 835-838
  • Marti MR, Zuber M, Oertli D, Weber WP, Müller D, Köchli OR, Wasmer S, Metzger J, Langer I, Harder F. Advanced Breast Biopsy Instrumentation for the evaluation of nonpalpable lesions: a reliable tool with little therapeutic potential. Eur J Surg 2001; 167:15-18
  • Gambazzi F, Zuber M, Oertli D, Marti W, Kocher Th, Torhorst J, Harder F. Kleine Mammakarzinome: weniger axilläre Chirurgie? Swiss Surg 2000; 6: 116-120
  • Langer I, Zuber M, Köchli OR, Kocher Th, Müller-Brand J, Torhorst J, Harder F. Validierungsstudie des sentinel lymph node Verfahrens beim invasiven Mammakarzinom. Eigene Daten und Review der Literatur. Swiss Surg 2000; 6: 128-136
  • Kocher Th, Zuber M, Langer I, Harder F. Bedeutung der endoskopischen Axilladissektion beim invasiven Mammakarzinom nach Einführung des sentinel lymph node Verfahrens. Swiss Surg 2000; 6: 121-127
  • Marti WR, Zuber M, Oertli D, Weber WP, Müller D, Köchli OR, Wasmer S, Metzger J, Langer I, Harder F. Die Advanced Breast Biopsy Instrumentation (ABBI) für die Evaluation mammographisch verdächtiger, nicht-palpabler Befund der Brustdrüse: Eine zuverlässige Diagnostik mit geringem therapeutischen Potential. Swiss Surg 2000; 6: 111-115
  • Demartines N, Eisner L, Schnabel K, Fried R, Zuber M, Harder F. Evaluation of resonance cholangiography in the management of bile duct stones. Arch Surg 2000; 135: 148-152
  • Zuber M, Kocher Th, Langer I, Harder F. Stellenwert der endoskopischen Axilladissektion beim invasiven Mammakarzinom. Acta Chir Austriaca 2000; 32: 1-5
  • Vorburger S, Zuber M, Renggli JC, Schnabel K. Das Fenster im Ligamentum falciforme. Ein seltener Fall einer Hernierung des Dünndarms durch das Ligamentum falciforme. Chirurg 2000; 71: 466-468
  • Eppenberger U, Küng W, Schläppi JM, Rösel JL. Benz Ch, Müller H, Matter A, Zuber M, Lüscher K, Litschgi M, Schmitt M, Foekens JA, Eppenberger-Castori S. Markers of tumor angiogenesis and proteolysis (VEGF, uPA) independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 1998; 16: 3129-3136
  • Oertli D, Zuber M, Müller D, Marti WR, Köchli OR, Torhorst J, Harder F. Erste Erfahrungen mit der Advanced Breast Biopsy Instrumentation (ABBI), einem System zur stereotaktischen Exzision nicht-palpabler Mammabefunde. Langenbecks Arch Surg, Surg Forum 1998; 383: 379-383
  • Kocher Th, Zuber M, Harder F. Die endoskopische Axilladissektion beim invasiven Mammakarzinom. Erste Erfahrungen mit einer neuen Technik. Zentralbl Chir 1998; 123: 98-99
  • Harder F, Zuber M, Kocher Th, Torhost J. Endoscopic surgery to the axilla - A replacement for conventional axillary clearance? Recent Results Cancer Res 1998; 152: 180-189
  • Metzger J, Krüss Ch, Kocher T, Ghisletta N, Zuber M, von Flüe M, Harder F. Mesh plug Operation: eine einfache, schnelle und komplikationsarme Technik zur Leistenhernien¬ver-sorgung. Schweiz Med Wochenschr 1998; 128: 1401-1407
  • Oertli D, Zuber M, Müller D, Marti WR, Köchli OR, Torhost J, Harder F. Advanced breast biopsy instrumentation (ABBI), ein System zur stereotaktischen Exzision mammographisch verdächtiger nicht-palpabler Befunde der Brustdrüse. Schweiz Med Wochenschr 1998; 6: 811-816
  • Harder F, Zuber M, Oertli D. Apparative Diagnostik zur Therapieentscheidung – was ist möglich und wünschenswert, was verzichtbar und was überflüssig – in der Mammachirurgie. Langenbecks Arch Chir 1997; 382: 391-394
  • Zuber M, Spagnoli G, Lüscher U, Kocher T, Schaefer Ch, Noppen Ch, Gudat F, Harder F, Heberer M. Heterogeneity of melanoma antigen-1 (MAGE-1) gene and protein expression in malignant melanoma. Eur Surg Res 1997, 29: 403-410
  • Noppen Ch, Lüscher U, Zuber M, Spagnoli G, Schaefer Ch. Detection of tumor-associated antigen gene expression in peripheral blood by RT-PCR in combination with the mRNA isolation kit for blood/bone marrow. Biochemica 1997; 4: 11-13
  • Schaefer Ch, Noppen Ch, Nürnberger H, Gudat F, Kocher Th, Lüscher U, Zuber M, Spagnoli G, Heberer M. Immunohistochemical detection of MAGE tumor-associated antigens in esophageal squamous cell carcinoma. Oncol Rep 1997; 4: 1289-1293
  • Fischer C, Gudat F, Stulz P, Noppen Ch, Schaefer Ch, Zajac P, Trutmann M, Kocher Th, Zuber M, Harder F, Heberer M, Spagnoli G. Immunohistochemical analysis of MAGE-3 protein expression in non small cell lung carcinomas. Int J Cancer 1997, 71: 1119-1121
  • Juretic A, Samija M, Spagnoli GC, Krajina Z, Zivkovic M, Herzeg T, Sobat H, Bistrovic M, Eljuga D, Turic m, Zuber M, Heberer M. Expression of cytokine genes in peripheral blood mononuclear cells of patients undergoing postmastectomy radiotherapy. Croatian Med J 1997; 38: 327-331
  • Juretic A, Jürgens-Göbel J, Schaefer Ch, Noppen C, Willimann T, Kocher Th, Zuber M, Harder F, Heberer M, Spagnoli G. Cytotoxic T-lymphocyte responses against mutated P21 ras peptides: an analysis of specific T-cell-receptor gene usage. Int J Cancer 1996, 68: 471-478
  • Gudat F, Zuber M, Dürrmüller U, Kocher Th, Schaefer Ch, Noppen Ch, Spagnoli G. The tumor-associated antigen MAGE-1 is detectable in formaline-fixed paraffin sections of malignant melanoma. Virchows Arch 1996, 429: 77-81
  • Zuber M, Heberer M, Lüscher U, Kocher Th, Harder F, Schaefer Ch, Gudat F, Spagnoli G. Heterogeneity of melanoma antigen-1 (MAGE-1) gene and protein expression in malignant melanoma. Surg Forum 1996, 47: 478-481
  • Kocher Th, Schraml P, Spagnoli G, Zuber M, Lüscher U, Harder F, Heberer M. Functional heterogeneity of melanoma cells of a single tumor biopsy. Langen¬becks Arch Chir, Chir Forum 1996; 381: 449-453
  • Zuber M, Heberer M, Luescher U, Kocher T, harder F, Schaefer C, Gudat F, Spagnoli GC. Heterogeneity of melanoma antigen-1 (MAGE-1) gene and protein expression in malignant melanoma. Surg Forum 1996; 478-481
  • Spagnoli G, Schaefer Ch, Willimann T, Kocher Th, Amoroso A, Juretic A, Zuber M, Lüscher U, Harder F, Heberer M. Peptide-specific CTL in tumor-infiltrating lympho¬cytes from metastatic melanomas expressing MART-1/Melan-A, gp 100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients. Int J Cancer 1995, 64: 309-315
  • Kocher Th, Spagnoli G, Lüscher U, Zuber M, Juretic A, Schaefer Ch, Willimann T, Harder F, Heberer M. Tumor-infiltrating lymphocytes from metastatic melanoma recognize tumor antigen-derived peptides: A clinical study in a series of consecutive, unselected HLA-A2-positive patients. Surg Forum 1995, 46: 539-541
  • Dupont V, Zuber M, Laffer U, Harder F. Lokale Behandlung des Mamma-Karzinoms: Wann ist eine brust¬erhaltende Therapie nicht geeignet? Zentralbl Chir 1995, 120: 551-555
  • Schultz E, Juretic A, Dellabona P Lüscher U, Siegrist W, Harder F, Heberer M, Zuber M, Spagnoli G. MAGE-1 gene product is a cytoplasmic protein. Int J Cancer 1994, 59: 435-439
  • Zuber M, Lüscher U, Spagnoli G, Filgueira L, Juretic A, Kocher Th, Schultz E, Caetano V, Harder F, Heberer M. Cytokine gene expression in metastatic melanoma. Surg Forum 1994, 45: 519-521
  • Zuber M, Filgueira L, Merlo A, Lüscher U, Juretic A, Spagnoli G, Harder F, Heberer M. Inter-aktion von Tumor und Immunsystem in Nierenzellkarzinomen und Melanomen. Zytokingen-Trans¬skription in Tumoren zum Zeitpunkt der chirurgischen Resektion. Schweiz Med Wo-chenschr 1994, 124: 930-935
  • Kocher Th, von Flüe M, Zuber M, Staub JJ, Scheidegger D, Harder F. Chirurgie beim Phäochromozytom. Entwicklung über 12 Jahre. Schweiz Med Wo¬chenschr 1994, 124: 953-956
  • Lüscher U, Filgueira L, Juretic A, Zuber M, Heberer M, Spagnoli G. The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor infiltrating lymphocytes. Int J Cancer 1994, 57: 612-619
  • Lüscher U, Zuber M, Filgueira L, Juretic A, Spagnoli G, Heberer M. Anerge Lymphozyten aus metastasie¬renden Melanomen können zu tumorspezifischer Zytotoxizität stimuliert werden. Langenbecks Arch Chir, Chir Forum 1994; 379: 373-377
  • Goedegebuure PS, Zuber M, Leonard-Vidal DL, Burger UL, Cusack JC Jr, Chang MP, Douville LM, Eberlein TJ. Reactivation of murine tumor-infiltrating lymphocytes with solid-phase anti-CD3 antibody: in vitro cytokine production is associated with in vivo efficacy. Surg Oncol 1994, 3: 79-89
  • Filgueira L, Zuber M, Merlo A, Lüscher U, Schultz E, Caetano V, Harder F, Garotta G, Spagnoli G, Heberer M. Differential effects of IL-2 and CD3 triggering on cytokine gene transcription and secretion in tumor infiltrating lympho¬cytes. Cell Immunol. 1993, 150: 205-218
  • Spagnoli G, Juretic A, Schultz E, Dellabona P, Filgueira L, Hörig H, Zuber M, Garotta G, Heberer M. On the relative roles of Interleukin-2 and Interleukin-10 in the generation of lymphokine activated killer cell activity. Cell Immunol 1993, 146: 391-405
  • Filgueira L, Zuber M, Merlo A, Caetano V, Schultz E, Juretic A, Harder F, Spagnoli G, Heberer M. Cytokine transcription in renal cell carcinomas. Br J Surg 1993, 80: 1322-1325
  • Merlo A, Filgueira L, Zuber M, Harder F, Gratzl O, De Libero G, Heberer M, Spagnoli G. T-cell receptor V-gene usage in neoplasms of the central nervous system: a comparative analysis in cultured tumor infiltrating and peripheral blood T cells. J Neurosurg 1993, 78: 630-637
  • Filgueira L, Zuber M, Merlo A, Harder F, Heberer M, Spagnoli G. Effects of dif¬ferent cultureprotocols on the expression of discrete T-cell receptor variable regions in human tumor infiltrating lymphocytes. Eur J Cancer 1993, 29: 1754-1760
  • Merlo A, Juretic A, Zuber M, Filgueira L, Lüscher U, Caetano V, Ulrich J, Gratzl O, Heberer M, Spagnoli G. Cytokine gene expression in primary brain tumors, metastases and meningeomas suggests specific transcription pattern. Eur J Cancer 1992, 29: 2118-2125
  • Spagnoli GC, Zuber M, Merlo A, Gaetano V, Schultze E, Harder F, Filgueira L, Heberer M. Cytokine gene-transcription in renal cell carcinomas – a polymerase chain reaction study in tumor biopsies. J Cell Biochem 1993; 129
  • Zuber M, Filgueira L, Merlo A, Spagnoli G, Harder F, Heberer M. Aktivierung humaner, tumor¬infiltrieren¬der Lymphozyten (TIL) mit Interleukin-2 und fest¬phasengebundenem anti-CD3 Anti¬körper. Langenbecks Arch Chir, Chir Forum 1992; 377: 239-245
  • Massaro AF, Schoof DD, Rubinstein A, Zuber M, Leonard-Vidal FJ, Eberlein TJ. Solid anti-CD3 anti¬body activation of murine tumor infiltrating lymphocytes. Cancer Res 1990, 50: 2587-2592
  • Eberlein TJ, Massaro AF, Rubinstein A, Leonard-Vidal FJ, Zuber M, Selleck C, Schoof DD. In vivo and in vitro effects of murine tumor infiltrating lymphocytes (TIL) restimulation by anti-CD3 antibody. Surg Forum 1989, 40: 428-430
  • Laffer U, Dürig M, Bloch HR, Zuber M, Stoll HR. Implantierbare Katheter¬systeme. Erfahrungen bei 205 Patienten. Dtsch med Wschr 1989, 114: 655-658
  • Rüedi Th, Balmer K, Zuber M. Die frischen Bandrupturen am oberen Sprungge¬lenk. Chirurg 1984, 55: 692-698
  • Wichtige Kommentare & Korrespondenzen
  • Dreyfuss JH. News & Views. Study finds omission of axillary lymph node dissection safe for patients with sentinel node micrometastases. CA A Cancer Journal for Clinicians 2010; 60: 2-3
  • Herrmann R, Lorenz M, Zuber M, Rufibach K, Laffer U. Perioperative and adjuvant chemotherapy in colon cancer: results of SAKK trial 40/93. Int J Colorectal Dis 2009; 24: 351-352
  • Fricker J. Sentinel node mapping for staging of colorectal cancer. The Lancet Oncology 2006; 7: 291
  • Zuber M. Invited commentary to: Yu JC et al. Prediction of metastases to non-sentinel nodes by sentinel node status and primary tumor characteristics in primary breast cancer in Taiwan. World J Surg 2005; 29: 813-819
  • Guller U, Oertli D, Zuber M. Correspondence to: Byrne AM et al. Positron emission tomography in the staging and management of breast cancer. Br J Surg 2004; 91: 1398-1409; www.bjs.co.uk/bjsCda/microViewCorrespondence.do
  • Originalarbeiten (Übrige)
  • Rueff J, Söllner O, Zuber M, Weixler B. Megaduodenum in a 59-year-old man: a very late postoperative complication after duodenal atresia. BMJ Case Rep 2018; doi: 10.1136/bcr-2017-221792
  • Zuber M, Langer I, Berclaz G, Köchli OR. Fundierter Sentinel Consensus dank Daten der Schweizerischen Multizenterstudie. News letter SGS 2004; 4: 11-12
  • Güller U, Zuber M, Marti WR, Heberer M, Oertli D. Challenges in performing clinical trials in surgical oncology. swiss knife 2004; 1: 23-25
  • Zuber M. Axilläres Staging beim Mammakarzinom in der Schweiz: Sentinel Lymphknoten (SLN) Biopsie: Standard of Care? News letter SGS 2003; 3: 4-6
  • Bittner C, Zuber M, Eisner L. Akute Ischämie der Hand bei einem Drogenabhängigen nach akzidenteller, intraarterieller Injektion. Swiss Surg 2002; 8: 281-284
  • Zuber M. Statement zur Sentinel Lymphonodektomie. News letter SGS 2002; 2: 3-4
  • Zuber M, Harder F. Mammakarzinom: Sentinel Lymph Node – Wächter intakter regionaler Lymphknoten. Praxis 2001; 90: 835-838
  • Viehl C, Nürnberger HR, Zuber M, Harder F. Pyoderma gangraenosum: Ausgedehnte Defektbildung in einer Mastektomiewunde. Chir Praxis 2001; 58: 63-68
  • Styger S, Demartines N, Zuber M, Harder F. Der chronische Magenvolvulus. Diagnostik und Therapie. Chir Praxis 2000; 57: 231-234
  • Kocher Th, Zuber M, Harder F. Die minimal-invasive Chirurgie beim Mamma¬karzinom. Ther Umschau 1997; 54: 540-544
  • Rothenbühler JM, Ackermann C, Zuber M. Die Technik der Gallengangs¬revision. Helv chir Acta 1990, 57: 153-155
  • Zuber M, Bodoky A, Ackermann C. Notfalldiagnostik beim Zökumvolvolus. Helv chir Acta 1990, 57: 37-40
  • Zuber M. Antibiotikaprophylaxe in der Kolorektalchirurgie mit Kefazolin (Kefzol) - Ornidazol (Tiberal) versus Cefazolin - Plazebo. Eine prospektive, randomi¬sierte und kontrollierte Dop-pelblindstudie. Dissertation, Universität Basel, 1990
  • Vogelbach P, Harder F et al. Prospektive Erfassungsstudie von 586 kon¬seku¬tiven fortlaufen-den, einreihi¬gen, extramukösen Kolonanastomosen. Helv chir Acta 1988, 55: 655-658
  • Zuber M, Dürig M, Neff U, Laffer U. Antibiotikaprophylaxe in der Kolonchirurgie: Chefazolin (Kefzol) - Omidazol (Tiberal) versus Cefazolin - Placebo. Helv chir Acta 1989, 56: 211-215
  • Balmer K, Rüedi Th, Zuber M. Die fibulare Bandverletzung am oberen Sprung¬gelenk. Beitrag zur Rönt¬gendiagnostik. Helv chir Acta 1985, 52: 201-204
  • Zuber M, Balmer K, Rüedi Th, Nachkontrolle operativ und konservativ behan¬delter lateraler Bandrupturen am oberen Sprunggelenk. Helv chir Acta 1984, 51: 633-640
  • Journal Herausgabe
  • Zuber M, Vonlanthen R (eds). swiss knife 2004 - 2008
  • de Roche R, Ziegler S, Casanova G, Dutoit M, Zuber M. fmch direct. 2004 - 2007
  • Zuber M, Viehl CT (eds). Symposium Biel 2001. Advances in surgical oncology.Part II. Swiss Surg 2002; 8 (2)
  • Zuber M, Viehl CT (eds). Symposium Biel 2001. Advances in surgical oncology. Part I. Swiss Surg 2001; 7 (6)
  • Zuber M, Harder F (eds). 5th Postgraduate course in surgical oncology, Basel 1999. Early invasive breast cancer. Part II. Swiss Surg 2000; 6 (3)
  • Zuber M, Harder F (eds). ). 5th Postgraduate course in surgical oncology, Basel 1999. Early invasive breast cancer. Part I. Swiss Surg 1999; 5 (5)
  • Zuber M, von Flue M (eds). 4th Postgraduate course in surgical oncology, Basel 1997. Colorectal cancer. Swiss Surg 1997; 3 (6)
  • Buchkapitel
  • Langer I, Guller U, Viehl CT, Zuber M. Sentinel lymph node metastases in breast cancer: prognostic relevance and therapeutic implications. Chapter in: From local invasion to metastatic cancer. Involvement of distant sites through the lymphovascular system. Leong SPL (ed). Humana Press / Springer. 2009: 339-345
  • Saha S, Sirop S, Soni M, Iddings D, Wiese D, Bilchik AJ, Beutler T, Ghanem M, Doan KA, Viehl CT, Zuber M. Sentinel lymph node mapping in colorectal cancer. Chapter in: From local invasion to metastatic cancer. Involvement of distant sites through the lymphovascular system. Leong SPL (ed). Humana Press / Springer. 2009: 361-379
  • Zuber M. Mammakarzinom. Kapitel in Viehl CT, Oertli D (Ed). Facharztprüfung Chirurgie. Ein Manual zur Prüfungsvorbereitung unter dem Patronat der Schweizerischen Gesellschaft für Chirurgie. 1. Auflage. EMH Scripts. 2009: 126-135
  • Oertli D, Zuber M. Milz. Kapitel in Siewert JR, Rothmund M, Schumpelick (Ed). Praxis der Viszeralchirurgie. Gastroenterologische Chirurgie 2. Auflage. Springer Verlag, Heidelberg 2006: 729-743
  • Saha S, Dan AG, Viehl CT, Zuber M, Wiese D. Sentinel lymph node mapping in colon and rectal cancer: its impact on staging, limitations, and pitfalls. Chapter in selective sentinel lymphadenectomy for human solid cancer. Leong SPL, Kitigawa Y, Kitajima M. (eds). Springer. Cancer Treat Res 2005; 127: 105-122
  • Zuber M, Harder F. Kolonvolvulus. Kapitel in Siewert JR, Harder F, Rothmund M (Ed). Praxis der Viszeralchirurgie. Gastroenterologische Chirurgie Band I. Springer Verlag, Heidelberg 2002; I: 518-531
  • Oertli D, Zuber M, Harder F. Milz. Kapitel in Siewert JR, Harder F, Rothmund M (Ed). Praxis der Viszeralchirurgie. Gastroenterologische Chirurgie Band I. Springer Verlag, Heidelberg 2002; I: 855-872
  • Zuber M, Harder F. Benign tumors of the colon and rectum. Evidence-based and problem-oriented. Holzheimer RG, Mannick JA (eds). W Zuckerschwerdt Verlag München, New York. 2001: 172-178
  • Zuber M, Kocher T, Oertli D, Gambazzi F, Müller D, Köchli O, Torhost J, Harder F. Das "sentinel lymph node"-Verfahren als Selektionskriterium für die axilläre Lymphknotendissektion beim Mammakarzinom. In: Laffer U, Oertli D, Dürig M, Harder F (Ed): Ethik, Technik und Konzepte: 10 Jahre später. Basler Beitr Chir, Schwabe, Basel 1998; 10: 209-216
  • Kocher Th, Zuber M, Oertli D, Harder F. Die endoskopische Axilladissektion beim invasiven Mammakarzinom - Erste Erfahrungen mit einer neuen Technik. In: Laffer U, Oertli D, Dürig M, Harder F (Ed): Ethik, Technik und Konzepte: 10 Jahre später. Basler Beitr Chir, Schwabe, Basel 1998: 10: 217-221
  • Oertli D, Zuber M, Müller D, Marti W.R. Köchli O.R. Torhost J, Harder F. Erste Erfahrungen mit der Advanced Breast Biopsy Instrumentation (ABBI), einem System zur stereotaktischen Exzision nicht-palpabler Mammabefunde. In: Laffer U, Oertli D, Dürig M, Harder F (Ed): Ethik, Technik und Konzepte: 10 Jahre später. Basler Beitr Chir, Schwabe, Basel 1998; 201-207
  • Zuber M. Leberkrebs. Serie: Patienteninformation (Faltblätter) der Schweizerischen Krebsliga, Bern 1997
  • Revision für den 15. Internationalen Praktischen Kurs für Gastro¬enterologische Chirurgie, Davos 1998
  • Überarbeitete Version für den 14. Internationalen Praktischen Kurs für Gastro¬enterologische Chirurgie, Davos 1997
  • Zuber M, Bertschi V (eds). Manuscript for practical exercises. Workshop in gastro¬intestinal surgery. International Gastrointestinal Surgery Workshop, Davos 1996
  • Revision für den 15. Internationalen Praktischen Kurs für Gastroenterologische Chirurgie, Davos 1998
  • Überarbeitete Version für den 14. Internationalen Praktischen Kurs für Gastroenterologische Chirurgie, Davos 1997
  • Zuber M, Bertschi V (Ed). Manuskript für praktische Übungen. 13. Internationaler Praktischer Kurs für Gastroenterologische Chirurgie, Davos 1996
  • Juretic A, Spagnoli G, Heberer M, Zuber M, Harder F, Samija M, Eljuga D, Turic M. Induction of a cytotoxic T lymphocyte response in vitro against peptides encompassing mutations in the ras oncogene. In: Osmak M, Skrk J (eds). Molecular oncology today. Proceedings of the Croatian-Slovenian Meeting, Zagreb 1996: 15-19
  • Zuber M. Gallenblasenkrebs. Serie: Patienteninformation (Faltblätter) der Schweizerischen Krebsliga, Bern 1995
  • Metzger U, Zuber M. Malignancies of the small bowel. In: Peckham M, Pinedo B, Veronesi U (Ed). Oxfort Textbook of Oncology. Oxford University Press, Oxford (GB) 1995: 1130-1133
  • Merlo A, Filgueira L, Zuber M, Lüscher U, Caetano V, Schultz E, Juretic A, Gratzl O, Spagnoli G, Heberer M. Nachweis der inhibitorischen Zytokine TGF- 2 und Interleukin-10 bei primären Neoplasien: Ursa¬che der funktionellen In¬aktivierung von tumorinfiltrierenden Lymphozyten? In: Laffer U, de Roche R, Harder F (eds). Modelle interdisziplinären Handelns. Basler Beitr Chir, Karger, Basel 1993; 5: 76-80
  • Zuber M, Filgueira L, Merlo A, Lüscher U, Caetano V, Schultz E, Juretic A, Harder F, Spagnoli G, Heberer M. Zytokintranskription in Nierenzellkazinomen. In: Laffer U, de Roche R, Harder F (Ed). Modelle interdisziplinären Handelns. Basler Beitr Chir, Karger, Basel 1993; 5: 81-85
  • Filgueira L, Spagnoli G, Zuber M, Merlo A, Gasser T, Bucheli B, Heberer M, Harder F. Differential TCR-V-gene usage in isolated human tumor infiltrating and autologous peripheral lymphocytes. In: Malavasi F, Cortese R, Albertini A (eds). European Biotechnology Today: The impact of basis science on diagnosis and therapy. Intercept Ltd, Andover (GB) 1992: 129-135
  • Zuber M, Laffer U, Harder F. Preventive Surgery. In: Weber W (ed). Familial cancer control. Monographs (Veronesi U, series ed) European School of Onco¬logy. Springer, Berlin, Heidel-berg, New York 1992: 59-64
  • Harder F, Vogelbach P, Zuber M. Die fortlaufende einreihige Darmanastomose. In: Lamesch A (ed). Moderne Konzepte und neue Techniken in der Kinder¬chirurgie. Bulletin de la Societé des Sciences medicales du Grand-Duche de Luxembourg, Chirurgie pédiatrique 1989; 126 III: 55-60
  • Zuber M, Frede KF. Der Zökumvolvolus. In: Laffer U, Dürig M (Ed): Ethik, Technik und Konzepte, Basler Beitr Chir. Karger, Basel 1989; 1: 125-131